Adeno-associated virus materials and methods
AssigneeChildren's Hospital, Inc.
InventorPhilip R. Johnson, Jr.
Life of this patent
Estimating the term…
Abstract
The present invention provides adeno-associated virus (AAV) materials and methods which are useful for DNA delivery to cells. More particularly, the invention provides recombinant AAV (rAAV) genomes, methods for packaging rAAV genomes, stable host cell lines producing rAAV and methods for delivering genes of interest to cells utilizing the rAAV. Particularly disclosed are rAAV useful in generating immunity to human immunodeficiency virus-1 and in therapeutic gene delivery for treatment of neurological disorders.
Claims4
A method for producing infectious recombinant adeno-associated virus comprising the step of infecting a mammalian host cell with a helper virus of adeno-associated virus,
- wherein the mammalian host cell is stably transfected with a recombinant adeno-associated virus genome and with adeno-associated virus rep-cap genes, and
- wherein the helper virus contains adeno-associated virus rep-cap genes inserted in its genome.
A method for producing infectious recombinant adeno-associated virus comprising the step of infecting a mammalian host cell with a helper virus of adeno-associated virus,
- wherein the mammalian host cell is stably transfected with a recombinant adeno-associated virus genome and with adeno-associated virus rep-cap genes,
- wherein the recombinant adeno-associated virus genome comprises adeno-associated virus inverted terminal repeats flanking DNA sequences encoding an immunodeficiency virus protein operably linked to promoter and polyadenylation sequences, and
- wherein the helper virus contains adeno-associated virus rep-cap genes inserted in its genome.
A method for producing infectious recombinant adeno-associated virus comprising the step of infecting a mammalian host cell with a helper virus of adeno-associated virus,
- wherein the mammalian host cell is stably transfected with a recombinant adeno-associated virus genome and with adeno-associated virus rep-cap genes,
- wherein the recombinant adeno-associated virus genome comprises adeno-associated virus inverted terminal repeats flanking DNA sequences encoding a polypeptide selected from the group consisting of tyrosine hydroxylase, aromatic amino acid decarboxylase, nerve growth factor, brain derived neurotrophic factor, NT-3, NT-4/5, glial derived neurotrophic factor and fibroblast growth factor, the DNA sequences being operably linked to promoter and polyadenylation sequences, and
- wherein the helper virus contains adeno-associated virus rep-cap genes inserted in its genome.
A method for producing infectious recombinant adeno-associated virus comprising the step of infecting a mammalian host cell with a helper virus of adeno-associated virus,
- wherein the mammalian host cell is stably transfected with a recombinant adeno-associated virus genome and with adeno-associated virus rep-cap genes,
- wherein the recombinant adeno-associated virus genome comprises the cytomegalovirus (CMV) immediate early promoter, the rabbit β-globin intron, the human immunodeficiency virus rev/envelope sequences and the rabbit β-globin polyadenylation signal, and
- wherein the helper virus contains adeno-associated virus rep-cap genes inserted in its genome.
Dependencies are inferred from the claim text.